全文获取类型
收费全文 | 766篇 |
免费 | 36篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 50篇 |
妇产科学 | 88篇 |
基础医学 | 106篇 |
口腔科学 | 8篇 |
临床医学 | 62篇 |
内科学 | 115篇 |
皮肤病学 | 16篇 |
神经病学 | 21篇 |
特种医学 | 118篇 |
外科学 | 48篇 |
综合类 | 13篇 |
一般理论 | 1篇 |
预防医学 | 68篇 |
眼科学 | 38篇 |
药学 | 32篇 |
中国医学 | 5篇 |
肿瘤学 | 25篇 |
出版年
2022年 | 4篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 12篇 |
2018年 | 15篇 |
2017年 | 11篇 |
2016年 | 7篇 |
2015年 | 14篇 |
2014年 | 17篇 |
2013年 | 34篇 |
2012年 | 20篇 |
2011年 | 23篇 |
2010年 | 25篇 |
2009年 | 26篇 |
2008年 | 21篇 |
2007年 | 44篇 |
2006年 | 31篇 |
2005年 | 17篇 |
2004年 | 22篇 |
2003年 | 18篇 |
2002年 | 18篇 |
2001年 | 26篇 |
2000年 | 17篇 |
1999年 | 23篇 |
1998年 | 37篇 |
1997年 | 42篇 |
1996年 | 31篇 |
1995年 | 21篇 |
1994年 | 22篇 |
1993年 | 26篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 14篇 |
1989年 | 20篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 9篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 3篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1977年 | 8篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1974年 | 3篇 |
1972年 | 5篇 |
1970年 | 2篇 |
排序方式: 共有821条查询结果,搜索用时 15 毫秒
31.
Although basal cell carcinoma is a very common malignancy, metastasis from this tumour is extremely rare. For this reason, many plastic surgeons, dermatologists and physicians dealing with skin malignancies consider this as a locally invasive malignancy. We present a rare case of metastatic basal cell carcinoma manifested as a bronchial tumour. This case highlights the fact that despite basal cell carcinoma’s local invasive potential, the possibility of distant metastasis still exists and clinicians should therefore be cautious about interpreting extracutaneous symptoms. Chest physicians should always consider the possibility of this rare tumour in the lungs in patients with a history of large basal cell carcinomas in the head and neck region. 相似文献
32.
Weisdorf DJ; Verfaillie CM; Davies SM; Filipovich AH; Wagner JE Jr; Miller JS; Burroughs J; Ramsay NK; Kersey JH; McGlave PB 《Blood》1995,85(12):3452-3456
Delay in hematologic recovery after bone marrow transplantation (BMT) can extend and amplify the risks of infection and hemorrhage, compromise patients' survival, and increase the duration and cost of hospitalization. Because current studies suggest that granulocyte- macrophage (GM) colony-stimulating factor (CSF) may potentiate the sensitivity of hematopoietic progenitor cells to G-CSF, we performed a prospective, randomized trial comparing GM-CSF (250 micrograms/m2/d x 14 days) versus sequential GM-CSF x 7 days followed by G-CSF (5 micrograms/kg/d x 7 days) as treatment for primary or secondary graft failure after BMT. Eligibility criteria included failure to achieve a white blood cell (WBC) count > or = 100/microL by day +21 or > or = 300/microL by day +28, no absolute neutrophil count (ANC) > or = 200/microL by day +28, or secondary sustained neutropenia after initial engraftment. Forty-seven patients were enrolled: 23 received GM-CSF (10 unrelated, 8 related allogeneic, and 5 autologous), and 24 received GM- CSF followed by G-CSF (12 unrelated, 7 related allogeneic, and 5 autologous). For patients receiving GM-CSF alone, neutrophil recovery (ANC > or = 500/microL) occurred between 2 and 61 days (median, 8 days) after therapy, while those receiving GM-CSF+G-CSF recovered at a similar rate of 1 to 36 days (median, 6 days; P = .39). Recovery to red blood cell (RBC) transfusion independence was slow, occurring 6 to 250 days (median, 35 days) after enrollment with no significant difference between the two treatment groups (GM-CSF: median, 30 days; GM-CSF+G- CSF; median, 42 days; P = .24). Similarly, platelet transfusion independence was delayed until 4 to 249 days (median, 32 days) after enrollment, with no difference between the two treatment groups (GM- CSF: median, 28 days; GM-CSF+G-CSF: median, 42 days; P = .38). Recovery times were not different between patients with unrelated donors and those with related donors or autologous transplant recipients. Survival at 100 days after enrollment was superior after treatment with GM-CSF alone. Only 1 of 23 patients treated with GM-CSF died versus 7 of 24 treated with GM-CSF+G-CSF who died 16 to 84 days (median, 38 days) after enrollment, yielding Kaplan-Meier 100-day survival estimates of 96% +/- 8% for GM-CSF versus 71% +/- 18% for GM-CSF+G-CSF (P = .026). These data suggest that sequential growth factor therapy with GM-CSF followed by G-CSF offers no advantage over GM-CSF alone in accelerating trilineage hematopoiesis or preventing lethal complications in patients with poor graft function after BMT.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
33.
Stephen Ip AbdulRazaq AH Sokoro Lisa Kaita Claudia Ruiz Elaine McIntyre Harminder Singh 《Journal canadien de gastroenterologie》2014,28(9):489-494
BACKGROUND:
The fecal occult blood test (FOBT), widely used as a colorectal cancer screening tool, continues to be used in hospitalized patients. However, the utility of this test for hospitalized patients is unclear.OBJECTIVE:
To assess FOBT use in a large urban regional health authority.METHODS:
Reports of all FOBTs performed between April 1, 2011 and March 30, 2012 from two academic and four community hospitals in Winnipeg (Manitoba) were extracted. Of 650 hospitalizations with a positive FOBT result and 1254 with a negative FOBT result, random samples of 230 and 97 charts, respectively, were reviewed. Information including demographics, admission diagnos(es), indication(s) for ordering the FOBT and clinical management was extracted.RESULTS:
Thirty-four percent (650 of 1904) of hospitalizations with an FOBT had a positive FOBT result. Family medicine physicians ordered approximately one-half of the reviewed FOBTs. The most common indication for ordering an FOBT was anemia. Of those with a positive FOBT, 66% did not undergo further gastrointestinal investigations. Of those with a positive FOBT and overt gastrointestinal bleeding and/or melena who underwent endoscopy, 60% had their endoscopy performed before the FOBT result being reported while 38% underwent their endoscopy ≥3 days after the stool sample was collected. There were minimal differences in clinical practices between academic and community hospitals.CONCLUSIONS:
The present study suggests that FOBT results in hospitalized patients may have little beneficial impact on clinical management. Hospital laboratories may be better served in directing resources to other tests. 相似文献34.
Achim Rosemann Adam Balen Brigitte Nerlich Christine Hauskeller Margaret Sleeboom‐Faulkner Sarah Hartley Xinqing Zhang Nick Lee 《The Hastings Center report》2019,49(3):30-42
A central problem for the international governance of heritable germline gene editing is that there are important differences in attitudes and values as well as ethical and health care considerations around the world. These differences are reflected in a complicated and diverse regulatory landscape. Several publications have discussed whether reproductive uses would be legally permissible in individual countries and whether clinical applications could emerge in the context of regulatory gaps and gray areas. Systematic comparative studies that explore issues related to the governance of this technology from different national and international perspectives are needed to address the lack of knowledge in this area. In this research report, we contribute to filling this gap by presenting views of stakeholders in the United Kingdom on challenges to the governance of heritable genome editing. We present findings from a multistakeholder study conducted in the United Kingdom between October 2016 and January 2018 and funded by the Wellcome Trust. This research included interviews, literature analysis, and a workshop. We involved leading U.K. scientists, in vitro fertilization clinicians, and representatives from regulatory bodies, patient organizations, and other civil societal organizations, as well as fertility companies. Part one of this article explores stakeholder perceptions of possible global developments in heritable genome editing and associated risks and governance challenges. Part two presents a range of policy options that were generated during the workshop in relation to the challenges discussed in part one. 相似文献
35.
37.
38.
It has been demonstrated that embryo transfer during IVF treatment can be performed competently and successfully by nurses (Barber et al., 1996). The present study has examined the success of nurses in training using the standardized protocol of this Unit. Initially, three nurses (two experienced (training completed) and one inexperienced (training ongoing)) each performed 80 transfers, which were standardized to three embryos replaced per transfer. The study aimed to establish whether a standardized procedure was undertaken by the nurses and to assess the influence of one inexperienced nurse performing the procedure. A further study (study 2) was performed to assess the influence of three inexperienced nurses against three experienced nurses undertaking the same procedures. In study 1, the pregnancy rates were 27.5%, 38.8% and 40.0% and there was no significant difference in the clinical pregnancy rates. In study 2, the pregnancy rates were 18.7%, 20.0% and 20.0% for the inexperienced nurses, and 26.3%, 30.0% and 32.5% for the experienced nurses. There was no significant difference in the clinical pregnancy rates within the inexperienced group or the experienced group. When the results of the three inexperienced nurses were grouped and were compared with those of the three experienced nurses, the pregnancy rates were 19.5% and 29.5%, respectively (P < 0.02). It has been shown that good clinical pregnancy rates can be achieved when nurses perform embryo transfer. There is no significant effect on clinical results when one nurse is in training; however, because of the expected learning curve, when three nurses train together a more significant effect is observed. 相似文献
39.
40.
Stratford GA Barth JH Rutherford AJ Balen AH 《Human fertility (Cambridge, England)》2000,3(3):203-206
Women presenting with infertility traditionally have been screened for thyroid function, yet recent guidelines have indicated that this is unnecessary in asymptomatic patients. A retrospective analysis of the results of routine thyroid function screening showed that occult thyroid dysfunction is common: 5.1% of the population studied had abnormal thyroid function tests. Therefore, it is recommended that assessment of thyroid function in women attending an infertility clinic should be continued. 相似文献